l-dopa therapy for Parkinson's disease: Past, present, and future

Parkinsonism and Related Disorders

Volumn 15, Issue 1, 2009, Pages

  Nagatsua, Toshiharu ^a,b   Sawadab, Makoto ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Dopamine; Dyskinesia; l dopa; Parkinson's disease; Selegiline

Indexed keywords

ANTIPARKINSON AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 58149120928     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70004-5     Document Type: Review

References (65)

1. Riederer P., Reichmann H., Janetzky B., Sian J., Lesch K.-P., Lange K.W., et al. Neurodegeneration in Parkinson's disease. Adv Neurol 86 (2001) 125-136
2. Nagatsu T., and Sawada M. Cellular and molecular mechanisms of Parkinson's disease: Neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiology 26 (2006) 781-802
3. Nagatsu T., Levitt M., and Udenfriend S. Tyrosine hydroxylase: The initial step in norepinephrine biosynthesis. J Biol Chem 239 (1964) 2910-2917
4. Cooksey C.J., Garratt P.J., Land E.J., Pavel S., Ramsden C.A., Riley P.A., et al. Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase. J Biol Chem 272 (1997) 26226-26232
5. Ikemoto K., Nagatsu I., Ito S., King R.A., Nishimura A., and Nagatsu T. Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra?. Neurosci Lett 253 (1998) 198-200
6. Lovenberg W., Weissbach H., and Udenfriend S. Aromatic l-amino acid decarboxylase. J Biol Chem 237 (1962) 89-93
7. Udenfriend S., and Wyngaarden J.B. Precursors of adrenal epinephrine and norepinephrine in vivo. Biochim Biophys Acta 20 (1956) 48-52
8. 14 in isolated perfused guinea pig heart. Science 139 (1963) 1299-1301
9. Carlsson A., Lindqvist M., and Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180 (1957) 1200
10. Carlsson A., Lindqvist M., Magnusson T., and Waldeck B. On the presence of 3-hydroxytyramine in brain. Science 127 (1958) 471
11. Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11 (1959) 490-493
12. Sano I., Kakimoto Y., Taniguchi K., Takeda M., Gamo J., and Nishimura K. Distribution of catechol compounds in human brain. Biochim Biophys Acta 32 (1959) 586-589
13. Sano I. Biochemistry of the extrapyramidal system. Shinkei Kenkyu No Shinnpo (Adv Neurol Sci) 5 (1960) 42-48 (Translated into English by Sano A. Parkinsonism Relat Disord 2000;6:303-6.)
14. Ehringer H., and Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidaren Systems. Klin Wochenschr 38 (1960) 1236-1239 (In German)
15. Foley P., Mizuno Y., Nagatsu T., Sano A., Youdim M.B.H., McGeer P., et al. The l-Dopa story - an early Japanese contribution. Parkinsonism Relat Disord 6 (2000) 1
16. Birkmayer W., and Hornykiewicz O. Der l-Dihydrophenylalanin (DOPA) - Effekt bei der Parkinson-akinese. Wien Klin Wochenschr 73 (1961) 787-788
17. Barbeau A., Murphy G.F., and Sourkes T.L. Excretion of dopamine in diseases of basal ganglia. Science 133 (1961) 1706-1707
18. Cotzias G.C., Papavasiliou P.S., and Gellene R. Modification of parkinsonism: Chronic treatment with l-DOPA. New Engl J Med 280 (1969) 337-345
19. Calne D.B., Karoum F., Ruthven C.R.J., and Sandler M. The metabolism of orally administered l-DOPA in Parkinsonism. Br J Pharmacol 37 (1969) 57-68
20. Bartholini G., Burkard W.P., Pletscher A., and Bates H.M. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature 215 (1967) 852-853
21. Axelrod J. O-methylation of epinephrine and other catecholamines in vitro and in vivo. Science 126 (1957) 400-401
22. Kuruma I., Bartholini G., Tissot R., and Pletscher A. The metabolism of l-3-O-methyl-dopa, a precursor of dopa in man. Clin Pharmacol Ther 12 (1971) 672-682
23. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 37 (1985) 333-364
24. Bonifácio M.J., Plama P.N., Almeida L., and Soares-da-Silva P. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 13 (2007) 352-379
25. ® treatment in Parkinson's disease: a long-term study. J Neural Transm 64 (1985) 113-127
26. Nagatsu T., and Sawada M. Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 72 (2007) 113-120
27. Huot P., and Parent A. Dopaminergic neurons intrinsic to the striatum. J Neurochem 101 (2007) 1441-1447
28. Kitahama K., Geffard M., Araneda S., Arai R., Ogawa K., Nagatsu I., et al. Localization of l-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry. Brain Res 1167 (2007) 56-70
29. Yamada H., Aimi Y., Nagatsu I., Taki K., Kudo M., and Arai R. Immunohistochemical detection of l-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci Res 59 (2007) 1-7
30. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27 (2007) 8138-8148
31. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
32. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., and Goetz C.G. Levodopa-induced dyskinesias. Move Disord 22 (2007) 1379-1389
33. Levandis G., Bazzini E., Armentero M.T., Nappi G., and Blandini F. Systemic administration of an mgluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesia in a rodent model of Parkinson's disease. Neurobiol Dis 29 (2008) 161-168
34. Morgese M.G., Cassano T., Cuomo V., and Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB(1) and TRPV1 receptors. Exp Neurol 208 (2007) 110-119
35. Lee J., Di Marzo V., and Brotchie J.M. A role for vanilloid receptor 1 (TRPV1) and endocarnnabinoid signaling of spontaneous and l-dopa induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51 (2006) 557-565
36. Olanow C.W., Obeso J.A., and Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clin Pract Neurol 2 (2006) 382-392
37. Stocchi F., Vacca L., Ruggieri S., and Olanow C.W. Intermittent versus continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62 (2005) 905-910
38. Carta M., Carlsson T., Kirik D., and Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (2007) 1819-1833
39. Carlsson T., Carta M., Winkler C., Björklund A., and Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesia in a rat model of Parkinson's disease. J Neurosci 27 (2007) 8011-8022
40. Rommelfanger K.S., Edwards G.L., Freeman K.G., Liles L.C., Miller G.W., and Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 104 (2007) 13804-13809
41. Misu Y., and Goshima Y. DOPA as a neurotransmitter candidate. In: Misu Y., and Goshima Y. (Eds). Neurobiology of DOPA as a neurotransmitter (2006), CRC Taylor & Francis, Boca Raton 23-34
42. Sanchez-Pernaute R., Jenkins B.G., Choi J.K., Chen Y., and Isacson O. In vivo evidence of D-3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias. Neurobiol Disease 27 (2007) 220-227
43. Bezard E., Brotchie J.M., and Gross C.E. Pathophysiology of levodopa-induced dyskinesia: potential or new therapies. Nature Rev Neurosci 2 (2001) 577-588
44. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005) 17-26
45. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102 (2005) 491-496
46. Santini E., Valjent E., Usiello A., Carta M., Borgkvist A., Girault J.-A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J Neurosci 27 (2007) 6695-7005
47. Bychkov E., Ahmed M.R., Dalbyk N., and Gurevich E.V. Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 102 (2007) 699-711
48. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Nat Acad Sci USA 101 (2004) 5099-5104
49. Beaulieu J.M., Sotnikova T.D., Marion S., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
50. Fahn S. Is levodopa toxic?. Neurology 47 Suppl 3 (1996) S184-S195
51. Agid Y. Levodopa: is toxicity a myth?. Neurology 50 (1998) 858-863
52. Weiner W.J. Levodopár toxic or neuroprotective?. Nature Clin Pract Neurol 2 (2006) 518-519
53. Segawa M., Nomura Y., and Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 54 Suppl 6 (2003) S32-S45
54. Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M., et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nature Genet 8 (1994) 236-242
55. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. New Engl J Med 351 (2004) 2498-2508
56. Holford N.H.G., Chan P.L.S., Nutt J.G., Kieburtz K., Shoulson I., and Parkinson Study Group. Disease progression and pharmacodynamics in Parkinson Diseasér vidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 33 (2006) 281-311
57. Chan P.L.S., Nutt J.G., and Hoford N.H.G. Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation. Pharmaceutical Res 24 (2007) 791-802
58. LeWitt P.A. Neuroprotection for Parkinson's disease. J Neural Transm Suppl 71 (2006) 113-122
59. Nagatsu T., and Sawada M. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm Suppl 71 (2006) 53-65
60. Youdim M.B.H., Edmondson D., and Tipton K.F. The therapeutic potential of monoamine oxidase inhibitors. Nature Rev Neurosci 7 (2006) 295-303
61. Pålhagen S., Heinonen E., Hägglund J., Kaugesaar T., Mäki-Ikola O., Palm R., and the Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 (2006) 1200-1206
62. Sumi-Ichinose C., Ichinose H., Takahashi E., Hori T., and Nagatsu T. Molecular cloning of genomic DNA and chromosomal assignment of the gene for human aromatic l-amino acid decarboxylase, the enzyme for catecholamine and serotonin biosynthesis. Biochemistry 31 (1992) 2229-2238
63. Muramatsu S., Fujimoto K., Ikeguchi K., Shimizu N., Kawasaki K., Ono F., et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Human Gene Therapy 13 (2002) 345-354
64. Fiandaca M., Forsayeth J., and Bankiewicz K.S. Current status of gene therapy trials for Parkinson's disease. Exp Neurol 209 (2008) 51-57
65. Eberling J.L., Jagust W.J., Christine C.W., Starr P., Larson P., Bankiewicz K.S., et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson's disease. Neurology (2008) in press.